image credit: Adobe Stock

European Health Data Space (EHDS) update: what this means for pharmaceutical and biotech

January 4, 2023

The intention is to streamline the process for patients wishing to access their medical records via electronic health record systems (“EHR systems”) and to facilitate the ability for researchers, innovators, and policy makers to use the data in a trusted and secure way that preserves privacy.

For pharmaceutical and biotech companies, this is a significant development and means that a broader pool of data could become accessible for research and development purposes. It should also assist from a standardisation and efficiency perspective, meaning that, across the EU, companies only have to comply with one set of rules, rather than grappling with multiple sets of regulations.

Read More on Pharmaphorum